The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
-
The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States, 35233
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
University of California Irvine, Irvine, California, United States, 92697
UCSD Moores Cancer Center, La Jolla, California, United States, 92093
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033
Stanford Cancer Center, Palo Alto, California, United States, 94304
University of California, Davis, Sacramento, California, United States, 95817
Yale University, New Haven, Connecticut, United States, 06520
University of Miami - Miller School of Medicine, Miami, Florida, United States, 33136
Emory University, Atlanta, Georgia, United States, 30322
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Aptose Biosciences Inc.,
Naval Daver, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
2026-12